LPTX – leap therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Pipeline Moves: Investigator-led trial of Lilly's merestinib in solid tumours terminated [Yahoo! Finance]
Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.
Form ARS LEAP THERAPEUTICS, INC. For: Dec 31
Form DEFA14A LEAP THERAPEUTICS, INC.
Form DEF 14A LEAP THERAPEUTICS, INC. For: Jul 02
Form SC 13G LEAP THERAPEUTICS, INC. Filed by: Samsara BioCapital, L.P.
Form SC 13G LEAP THERAPEUTICS, INC. Filed by: GILEAD SCIENCES, INC.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.